Amicus Therapeutics Stock Market Value
| FOLD Stock | USD 9.66 0.16 1.68% |
| Symbol | Amicus |
Amicus Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 1.629 | Quarterly Revenue Growth 0.367 | Return On Assets 0.0116 | Return On Equity (0.67) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Amicus Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Amicus Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Amicus Therapeutics.
| 11/29/2023 |
| 11/23/2024 |
If you would invest 0.00 in Amicus Therapeutics on November 29, 2023 and sell it all today you would earn a total of 0.00 from holding Amicus Therapeutics or generate 0.0% return on investment in Amicus Therapeutics over 360 days. Amicus Therapeutics is related to or competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rar... More
Amicus Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Amicus Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Amicus Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 18.26 | |||
| Value At Risk | (3.58) | |||
| Potential Upside | 3.16 |
Amicus Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amicus Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Amicus Therapeutics' standard deviation. In reality, there are many statistical measures that can use Amicus Therapeutics historical prices to predict the future Amicus Therapeutics' volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.67) | |||
| Treynor Ratio | (0.54) |
Amicus Therapeutics Backtested Returns
Amicus Therapeutics secures Sharpe Ratio (or Efficiency) of -0.1, which signifies that the company had a -0.1% return per unit of risk over the last 3 months. Amicus Therapeutics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Amicus Therapeutics' Mean Deviation of 1.55, standard deviation of 2.51, and Risk Adjusted Performance of (0.07) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.5, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Amicus Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Amicus Therapeutics is expected to be smaller as well. At this point, Amicus Therapeutics has a negative expected return of -0.26%. Please make sure to confirm Amicus Therapeutics' kurtosis, market facilitation index, and the relationship between the value at risk and rate of daily change , to decide if Amicus Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.09 |
Very weak reverse predictability
Amicus Therapeutics has very weak reverse predictability. Overlapping area represents the amount of predictability between Amicus Therapeutics time series from 29th of November 2023 to 27th of May 2024 and 27th of May 2024 to 23rd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Amicus Therapeutics price movement. The serial correlation of -0.09 indicates that less than 9.0% of current Amicus Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.09 | |
| Spearman Rank Test | -0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 0.51 |
Amicus Therapeutics lagged returns against current returns
Autocorrelation, which is Amicus Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Amicus Therapeutics' stock expected returns. We can calculate the autocorrelation of Amicus Therapeutics returns to help us make a trade decision. For example, suppose you find that Amicus Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Amicus Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Amicus Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Amicus Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Amicus Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Amicus Therapeutics Lagged Returns
When evaluating Amicus Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Amicus Therapeutics stock have on its future price. Amicus Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Amicus Therapeutics autocorrelation shows the relationship between Amicus Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Amicus Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:Check out Amicus Therapeutics Correlation, Amicus Therapeutics Volatility and Amicus Therapeutics Alpha and Beta module to complement your research on Amicus Therapeutics. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Amicus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.